One such strategy involved AAV9-mediated myocardial delivery of a peptide inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII) in RYR2R176Q mice, which successfully suppressed spontaneous calcium release and ventricular arrhythmias [103]. Here, CAMK2G is linked to Ventricular arrhythmia.